斯帕森坦有哪几个版本?分别多少钱?

Sparsentan is a drug used to treat primary immunoglobulin A nephropathy (IgAN). Its main versions include 200 mg and 400 mg. This article will delve into the different versions, prices, availability and medical insurance of sparsentin in the Chinese market, and provide patients with detailed information.

What versions of sparsentan are available

200 mg tablets

A 200 mg film-coated immediate-release oral tablet is provided. This tablet is suitable for use at the beginning of treatment, 200 mg once daily, and can be increased to the recommended dose after 14 days. This is an ideal option for patients who may need to gradually increase their dose to reduce the risk of side effects.

For some specific patient groups, such as those with liver impairment or the elderly, doctors may recommend starting with a lower dose to better monitor drug response.

400 mg tablets

As the primary option for maintenance therapy, 400 mg of FILSPARI is the standard dose for the treatment of IgAN and is designed to slow the risk of renal function decline. Tablets of this strength are designed for long-term use to help patients effectively manage disease progression.

In clinical studies, the 400 mg dose was shown to have a significant effect on reducing urine protein/creatinine ratio (UPCR) and stabilizing estimated glomerular filtration rate (eGFR).

How much do the different versions of Sparsentan cost?

Price

Sparsentan is developed by the American company Travere Therapeutics. The specification of a box is 400mgx30 tablets. The price of a box is about US$15,348. It is relatively expensive and patients need to buy it at their own expense. Because the drug is not yet included in the public health insurance systems of most countries, patients often have to bear high costs themselves.

Cost Considerations

Considering the cost of medications, many patients may seek different avenues to reduce their financial burden, such as through charitable aid programs or finding international price differentials.

Sparsentan’s marketing and medical insurance status in China

Market status

Sparsentan has not yet been marketed in my country, and has not been included in the scope of medical insurance reimbursement. Domestic patients are currently unable to purchase this drug directly on the domestic market, and they are not covered by medical insurance.

Import channels

For Chinese patients who want to try sparsentane treatment, they may need to obtain the drugs through personal importation, which usually involves complex processes and high costs. In addition, attention must be paid to the authenticity and quality assurance of drugs.

In view of the potential of sparsentan in the treatment of IgAN, relevant departments are actively working to promote the registration and approval process of the drug in China, and hope to include it in the medical insurance catalog as soon as possible, so that more patients can benefit.